Immupharma Plc (LON:IMM) Non-Executive Chairman Tim McCarthy talks to DirectorsTalk about the latest interim’s (for the 6 month period ending 30th June 2017), the current status of the Phase III
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2017. Key Highlights — Lupuzor(TM) :
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today confirmed a further update on Lupuzor™ its lead programme for the potential breakthrough compound for Lupus, the life threatening
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm a further update on Lupuzor(TM) its lead programme for the potential breakthrough compound for Lupus, the
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has given DirectorsTalk an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor(TM), its lead programme
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has confirmed that it will be announcing its Interim results for the six months ended 30 June 2017 on Wednesday 27
Northland Capital’s Vadim Alexandre discusses ImmuPharma in this exclusive interview with DirectorsTalk
Immupharma Plc (LON:IMM) is the topic of conversation when Head of Research at Northland Capital Partners Vadim Alexandre caught up with DirectorsTalk. Vadim provides his thoughts on the key points
https://www.youtube.com/watch?v=QKzZePfbWs8 ImmuPharma PLC is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such
Northland Capital Analyst said this morning “ImmuPharma issued another positive trial update on its flagship drug, Lupuzor, a potential treatment for Lupus. The Phase 3 trial continues to progress to
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
